The Polycomb group (PcG) proteins regulate stem cell differentiation via the repression of gene transcription, and their deregulation has been widely implicated in cancer development. The PcG protein Enhancer of Zeste Homolog 2 (EZH2) works as a catalytic subunit of the Polycomb Repressive Complex 2 (PRC2) by methylating lysine 27 on histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. In skeletal muscle progenitors, EZH2 prevents an unscheduled differentiation by repressing muscle-specific gene expression and is downregulated during the course of differentiation. In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma thought to arise from myogenic precursors, EZH2 is abnormally expressed and its downregulation in vitro leads to muscle-like differentiation of RMS cells of the embryonal variant. However, the role of EZH2 in the clinically aggressive subgroup of alveolar RMS, characterized by the expression of PAX3-FOXO1 oncoprotein, remains unknown. We show here that EZH2 depletion in these cells leads to programmed cell death. Transcriptional derepression of F-box protein 32 (FBXO32) (Atrogin1/MAFbx), a gene associated with muscle homeostasis, was evidenced in PAX3-FOXO1 RMS cells silenced for EZH2. This phenomenon was associated with reduced EZH2 occupancy and H3K27me3 levels at the FBXO32 promoter. Simultaneous knockdown of FBXO32 and EZH2 in PAX3-FOXO1 RMS cells impaired the pro-apoptotic response, whereas the overexpression of FBXO32 facilitated programmed cell death in EZH2-depleted cells. Pharmacological inhibition of EZH2 by either 3-Deazaneplanocin A or a catalytic EZH2 inhibitor mirrored the phenotypic and molecular effects of EZH2 knockdown in vitro and prevented tumor growth in vivo. Collectively, these results indicate that EZH2 is a key factor in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells working, at least in part, by repressing FBXO32. They also suggest that the reducing activity of EZH2 could represent a novel adjuvant strategy to eradicate high-risk PAX3-FOXO1 alveolar RMS.
INTRODUCTION
Rhabdomyosarcomas (RMS) are heterogeneous highly malignant tumors, which account for 7-8% of all pediatric malignancies and over half of the soft-tissue sarcomas in children. RMS are classically subdivided in two major histotypes: embryonal (around 70-80%) and alveolar (around 20-30%), the latter often metastatic at diagnosis and showing a high risk of recurrence. 1 In 70% of cases, alveolar RMS is characterized by the chromosomal translocation t(2;13) or t(1;13), resulting in myogenic differentiation leads to the loss of malignant phenotype in vitro and in vivo. [3] [4] [5] [6] In vertebrates, Polycomb Group proteins form two main groups of multiprotein complexes, Polycomb Repressive Complex (PRC)-1 and PRC2. 7 The enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of PRC2, methylates lysine 27 of histone H3 (H3K27me3), a hallmark of PRC2-mediated gene repression. 8 EZH2 is downregulated during progenitor cell differentiation, being undetectable in adult specialized cells and tissues. 8 Conversely, EZH2 is abnormally expressed in a wide range of tumors, with its level of expression being correlated with cancer aggressiveness. 8 In undifferentiated muscle cells, EZH2-mediated trimethylation of H3K27 contributes to maintaining the chromatin of muscle genes in a conformation repressive for transcription, supporting the self-renewal and proliferation of progenitor cells. [9] [10] [11] [12] [13] At the onset of differentiation, downregulation of EZH2 allows a chromatin conformation permissive for transcription of differentiation genes. [11] [12] [13] These data highlight the importance of EZH2 in controlling the balance between proliferation and differentiation of myogenic progenitors.
A number of reports have shown that aberrant overexpression of EZH2 in human cancers is often associated with poor prognosis. [14] [15] [16] [17] [18] EZH2 is expressed in undifferentiated stem-like cancer cells and promotes cancer cell proliferation and metastasis formation by repressing several tumor suppressor genes. 15, [19] [20] [21] [22] [23] [24] Notably, its molecular or pharmacological inhibition leads to the reversal of the malignant phenotype. [24] [25] [26] [27] [28] [29] Collectively, these findings demonstrate a role of EZH2 as a potential prognostic marker and therapeutic target in cancer. We and others have recently reported that (i) as compared with the normal myoblasts and muscle tissues EZH2 is markedly overexpressed in RMS 30, 31 and (ii) EZH2 downregulation in vitro leads to myogenic-like differentiation of an embryonal RMS cell line. 32 However, the role of EZH2 in the aggressive PAX3-FOXO1 alveolar RMS cells has not been evaluated, and the effect of EZH2 inhibition on the tumorigenic phenotype remains to be tested.
In the present work, we sought to evaluate the response of alveolar RMS expressing the PAX3-FOXO1 oncoprotein to EZH2 inhibition and to dissect the underlying molecular mechanisms. We show that EZH2 depletion induced apoptosis of this subtype of RMS cells in part through the derepression of the EZH2 target gene F-box protein 32 (FBXO32), also known as Atrogin1/MAFbx. Consistently, FBXO32 depletion rescues, whereas its overexpression facilitates, the pro-apoptotic effect of EZH2 silencing.
Pharmacological inhibition of EZH2 using 3-Deazaneplanocin A (DZNep), an S-adenosyl-L-homocysteine hydrolase inhibitor that induces proteosome-mediated degradation of EZH2, 25 or MC1945, a catalytic EZH2 inhibitor, 33, 34 phenocopies EZH2 knockdown effects in vitro and hampers tumor xenograft growth in vivo. Altogether, these results identify a key function of EZH2 in promoting the survival of PAX3-FOXO1 alveolar RMS that involves, at least partially, the modulation of FBXO32 expression. They also indicate that affecting EZH2 activity either by depletion or by inactivation could provide an anticancer strategy in this high-risk subgroup of pediatric soft-tissue sarcomas.
RESULTS
EZH2 protein levels are elevated in human PAX3-FOXO1 RMS primary samples and cell lines We first evaluated whether, as we recently reported for EZH2 transcripts, 30, 31 EZH2 protein levels were higher in PAX3-FOXO1 RMS tumor samples than in normal muscle tissue. EZH2 was studied using immunohistochemical analysis on 10 primary samples from PAX3-FOXO1-bearing alveolar RMS patients (Supplementary Table 1 ). EZH2 nuclear staining was detected in all the RMS specimens tested with median values ranging from 46 to 92% of positive nuclei per section, whereas normal muscles were negative (Figure 1a ).
In line with data on primary tumors, EZH2 levels were higher in PAX3-FOXO1-positive alveolar RMS cell lines compared with control skeletal myoblasts (skeletal muscle cells) and the protein was mostly localized in the nuclear-enriched fractions (Figure 1b) . Moreover, unlike what typically observed in myoblasts during differentiation, EZH2 levels were not modulated when RMS cells were incubated in differentiation culture conditions (low serum-containing medium) (Figure 1c) . 11 These findings imply that EZH2 expression and/or stability is deregulated in PAX3-FOXO1 alveolar RMS. Downregulation of EZH2 prevents PAX3-FOXO1 RMS cell proliferation As EZH2 expression sustains the proliferation of skeletal muscle precursors, [9] [10] [11] we sought to examine the effect of EZH2 depletion on the proliferation potential of the PAX3-FOXO1 alveolar cell line RH30 cultured in a proliferation (growth) medium. Cells were subjected to a double round (24 h) of RNA interference with a previous validated pool of siRNAs against EZH2 to warrant efficient and sustained silencing and analyzed starting from 24 h after the first siRNA transfection. Interestingly, EZH2-depleted RH30 cells were unable to proliferate showing 12 ± 3.5% survival 3 days after siRNA treatment (Figure 2a) , as detected by trypan blue exclusion. EZH2 silencing was confirmed by western blot from 24 h onward (Figure 2b ). Consistently, a global decrease in H3K27me3, but not in trimethylated Lys4 (H3K4me3), was detected at day 3 post-EZH2 siRNA transfection (Figure 2c ). These results indicate that EZH2 has a role in the proliferation and survival of PAX3-FOXO1 alveolar RMS cells.
Knockdown of EZH2 promotes apoptosis of PAX3-FOXO1 alveolar RMS cells EZH2 depletion in RH30 and RH4, another PAX3-FOXO1 alveolar RMS cell line, resulted in an increase of the percentage of cells in the subG1 cell-cycle phase compared with control siRNA cells (28 ± 3 and 26 ± 2%, respectively) ( Figure 3a) . This was associated with a decrease of the percentage of cells in G1 and S phases (30±6 and 11±3%, and 28±8 and 10±2%, respectively) and an increase by 20 ± 3 and 18 ± 5% of cells in G2 phase, respectively (Figure 3a) . Among the pro-apoptotic genes derepressed upon EZH2 knockdown, we annotated the ubiquitin ligase FBXO32 (Atrogin 1/MFAbx) (Figures 3b and c) , a tumor suppressor gene that is repressed by EZH2 in several tumor cell types. 23 In contrast, the expression of another known pro-apoptotic EZH2 target gene BIM and that of BAX were not upregulated 48 h after EZH2 silencing in both cell lines (Figures 3b and c) . Further, a decrease in Myogenin, MyoD and BCL2 protein levels and the appearance of a PARP-1-cleaved band in EZH2 siRNA cells compared with untreated or control siRNA cells (Figure 3c ) indicated that the differentiation program was inhibited in favor of programmed cell death. The same effect was obtained in RH30 cells transfected with an siRNA targeting the 5 0 -UTR of EZH2 mRNA already used in our lab 22 ( Supplementary Figures 1a and b) or infected with a lentivirus expressing a short hairpin RNA against EZH2 ( Supplementary Figures 1c and d) . Altogether, these results rule out siRNA off-target effects.
Conversely to what was observed in PAX3-FOXO1 RMS cells, EZH2 siRNA-mediated depletion in skeletal muscle cells cultured in GM resulted in no modulation in FBXO32 transcript levels 48 h post siRNA treatment and was associated to sustained Myogenin mRNA and protein induction 48 and 96 h after silencing, respectively, compared with control siRNA cells ( Supplementary  Figures 2a and b) . These findings confirm that the downregulation of EZH2 in normal myoblasts determine the triggering of a differentiation program as already reported. 11, 35, 36 Finally, biochemical rescue experiments using a retroviral vector expressing the murine EZH2 (not targeted by the used EZH2 siRNA) abolished the upregulation of FBXO32 in EZH2-depleted EZH2 supports PAX3-FOXO1 rhabdomyosarcoma survival R Ciarapica et al Figure 3) , indicating that the effect on FBXO32 expression is mediated by EZH2.
RH30 cells (Supplementary
Derepression of FBXO32 has a role in apoptosis induced by EZH2 depletion in PAX3-FOXO1 alveolar RMS cells In agreement with cell cycle results and with data in Supplementary  Figure 1 , EZH2 siRNA transfection increased the percentage of Annexin V-positive (apoptotic) cells from 14±3% in control siRNA to 46±5% and from 14±4 to 53±7% in RH30 and RH4 cells, respectively (Figures 4a and b ). Despite transfection with control siRNA showed a slight cytotoxic effect compared with the untransfected condition, the difference between control and EZH2 siRNA treatments was remarkable. Conversely, no Annexin V-positive cell population was detected after EZH2 knockdown in skeletal muscle cells cultured in GM (Supplementary Figure 2c) highlighting, once more, the different effects of this approach in a diverse cellular microenvironment. Notably, the percentage of Annexin V-positive cells decreased by 50% in EZH2-depleted RMS cells co-transfected with an FBXO32 siRNA. In contrast, enforced overexpression of 
FBXO32 is directly targeted by EZH2 in PAX3-FOXO1 alveolar RMS cells
To confirm that FBXO32 is a target gene of EZH2 in our cell context, we performed chromatin immunoprecipitation assays to evaluate the binding of EZH2 and the H3K27me3 status on the FBXO32 promoter. Figure 5a shows that EZH2 recruitment decreased in EZH2-silenced RH30 cells as compared with control siRNA cells and this paralleled with a decrease in the levels of H3K27me3 at the Polycomb-dependent FBXO32 promoter, pointing to FBXO32 as a direct target of EZH2 in PAX3-FOXO1 alveolar RMS. We previously reported that the Jumonji family member JARID2 cooperates with components of the PRC2 complex to regulate the H3K27me3 status on muscle regulatory genes in both embryonal and alveolar RMS cells. However, as shown in Supplementary Figure 5 , JARID2 depletion by siRNA in PAX3-FOXO1 alveolar RMS cells did not affect H3K27me3 levels at the FBXO32 promoter, as already reported in other cell contexts. 37, 38 Moreover, gene expression profiling data for 101 RMS previously described patient samples in the ITCC/CIT data set (Innovative Therapies for Children with Cancer/Carte d'Identité des Tumeurs) 1 within the R2 online platform 39 relative to publicly available Affymetrix expression profiling data for skeletal muscle samples (GSE9103), indicated that FBXO32 expression is much lower in RMS patient samples relative to skeletal muscle (Figure 5b ), which is in direct contrast to EZH2 levels in RMS patient samples where EZH2 is overexpressed, as previously reported by our group. 30 Finally, the analysis of the RMS patient sample set also showed a significant negative correlation between FBXO32 and EZH2 expression in RMS patient samples (R ¼ À 0.5, P ¼ 1.0e À 07), once again indicating an inverse relationship between the levels of these two proteins that supports their functional interactions ( Figure 5c ).
Altogether, these results suggest that EZH2 directly regulates FBXO32 expression in PAX3-FOXO1 alveolar RMS cells and that it could also be involved in maintaining low expression levels in vivo.
Pharmacological inhibition of EZH2 prevents PAX3-FOXO1 RMS cell proliferation As no direct catalytic EZH2 inhibitors were commercially available so far, we decided to pharmacologically inhibit EZH2 through two different approaches by treating cells with either (i) the S-adenosyl-L-homocysteine hydrolase inhibitor DZNep that indirectly inhibits EZH2 function mainly through degradation 23, 24, 40 or (ii) a catalytic EZH2 inhibitor, MC1945, the more recent synthesized compound from a family of EZH2 inhibitors validated against a panel of histone methyltransferases. 33, 34 In preliminary experiments, MC1945 behaved similarly but at lower doses to the family-related EZH2 catalytic inhibitor MC1948 (Supplementary Figure 6 ) previously used by our group to inhibit EZH2 in myoblasts 41 and was therefore used in the subsequent assays. This experimental strategy was aimed at evaluating the ability of two different pharmacological types of inhibition to mimic the effects of siRNA-mediated depletion of EZH2 in vitro.
First, we characterized the effects of DZNep and MC1945 on the proliferation of PAX3-FOXO1-positive RMS cells and their capability to reduce H3K27marks. As shown in Figure 6a , 96 h treatment with 5 mM of either DZNep or MC1945 achieved a significant inhibition of cell proliferation compared with vehicle-treated or untreated cells, respectively. DZNep treatment resulted in the downregulation of EZH2 protein levels, whereas, in line with a role as a catalytic inhibitor, MC1945 treatment did not affect them. Importantly, both treatments resulted in a marked decrease in global levels of H3K27me3 (Figure 6b ), as previously reported, 25, 40, 41 whereas the levels of H3K9me3, another repressive mark, remained unchanged demonstrating that they act mainly through inhibition of EZH2-containing complexes at the used doses on the basis of previous reports for DZNep. 24, 40, [42] [43] [44] [45] Consistently with EZH2 silencingdependent effects, the appearance of apoptotic Annexin V-positive cells was seen in both DZNep-and MC1945-treated RH30 cells ( Figure 6c ) associated with transcriptional upregulation of FBXO32 gene and decreased Myogenin levels after 72 h (Figure 6d ). Collectively, these observations indicate that pharmacological approaches either favoring the degradation or blocking the catalytic functions of EZH2 affect the proliferative potential of PAX3-FOXO1-positive alveolar RMS cells and mirror the effect of siRNA-and short hairpin RNAmediated EZH2 depletion in derepressing FBXO32.
Pharmacological inhibition of EZH2 prevents PAX3-FOXO1 RMS tumor growth in vivo
We then evaluated whether inhibition of EZH2 functions through DZNep or MC1945 treatment could be a potential approach to treat PAX3-FOXO1 RMS also in vivo. Nude mice were inoculated with RH30 cells and, when tumors became palpable, intraperitoneally treated either with 2.5 mg/kg DZNep, a previously reported non-toxic dose in these conditions, or with a vehicle. 19, 24 DZNep treatment resulted in a significant reduction in xenograft tumor volume (Figure 7a , left panels) and was associated with a decrease in the number of EZH2-and Ki67-positive cells (Figure 7b , upper panels). In agreement with in vitro results, a marked decrease in EZH2 protein levels was detected in DZNeptreated xenografts (Figure 7c ). Similar results were obtained when mice were treated with 2.5 mg/kg of MC1945 (Figure 7a , right panels), which did not decrease EZH2 levels, as previously shown in vitro and confirmed here in xenografts using immunohistochemical analysis. An increase in TUNEL-positive cells was observed for both treatments consistent with the triggering of a pro-apoptotic program (Figure 7b , lower panels). Collectively, our data provide evidence that EZH2 overexpression supports the survival of PAX3-FOXO1 alveolar RMS cells in vivo and suggest that targeting EZH2 might inspire novel therapeutic approaches to treat these high-risk alveolar RMS.
DISCUSSION
We have previously shown that EZH2 mRNA is overexpressed in cell lines and primary samples of pediatric RMS. 30, 31 Moreover, EZH2 knockdown has been shown to induce in vitro differentiation of cells of the embryonal RMS subtype. 32 However, the effects of EZH2 downregulation in PAX3-FOXO1 alveolar RMS, clinically and molecularly distinct from the embryonal subtype 1,46-48 and considered as the highest-risk form of RMS, 2 remained unknown. The present work was aimed at evaluating whether the modulation of EZH2 could affect tumorigenesis and at dissecting the molecular events that underlie EZH2 function in this subgroup of RMS. We show here that, in addition, the EZH2 protein levels are significantly higher in PAX3-FOXO1 alveolar RMS primary tissues as compared with the normal muscle tissues. Moreover, unlike what happens in normal myoblasts, 11, 35 the differentiation cue due to cell culture in the lowserum medium is unable to modulate the EZH2 levels in PAX3-FOXO1 alveolar RMS cells, indicating a tumor-specific deregulation.
We show here that EZH2 depletion highly affects PAX3-FOXO1 RMS cell survival leading to apoptosis. We then provide evidence that this phenomenon is due, at least in part, to the derepression of the tumor suppressor gene FBXO32, already shown to be induced by EZH2 knockdown in cells of solid and blood EZH2 supports PAX3-FOXO1 rhabdomyosarcoma survival R Ciarapica et al cancers. 23, 28, 40 Indeed, the simultaneous depletion of FBXO32 and EZH2 greatly reduced the apoptotic cell response, suggesting that EZH2 protects fusion-positive alveolar RMS cells from apoptosis in part by repressing FBXO32. Of note, FBXO32 derepression is associated with both a reduction in EZH2 recruitment and a decrease in H3K27me3 mark to the FBXO32 gene promoter, indicating that in our cell context EZH2 is recruited at this promoter and is enzymatically active to repress transcription, as already shown. 23, 40 FBXO32, also known as Atrogin-1/MAFbx, is a musclespecific E3 ligase involved in the massive protein degradation during muscle atrophy 49 and is a FOXO1 target gene in atrophic muscle. 50 However, there is no evidence for PAX3-FOXO1 directly regulating FBXO32 from analyses of ChIPseq data. 51 Recently, it has been shown that, in rat myoblasts in vitro, expression of FBXO32, which is induced in these cells by serum starvation, facilitates myogenesis through the repression of myocardin. 52 Intriguingly, both muscle atrophy and myogenesis involve apoptosis. [53] [54] [55] Moreover, the evidence that a same factor could have opposite effects on skeletal muscle, depending on the context, is not new and exemplified by Myogenin that can promote differentiation or degradation in different muscle microenvironments. 56 Therefore, the function of FBXO32 could be dependent from the molecular background and cellular normal or cancerous context. Consistent with this idea, ectopic FBXO32 overexpression, although unable to induce per se consistent apoptosis, markedly enhances the cell death response in EZH2 knocked down cells, suggesting that it is required but insufficient to do so. It is, thus, conceivable that FBXO32 expression may need to coordinate with other molecular events activating a global apoptotic program to sustain apoptosis in PAX3-FOXO1 RMS cells. This hypothesis is supported by the concomitant protein downregulation of Myogenin and MyoD seen in EZH2-depleted cells, the latter known as directly targeted by FBXO32 for degradation in myoblasts, [57] [58] [59] testifying the inability of our cells to undergo differentiation. 32 In addition, a decrease in BCL2, which has been shown to be degraded in cardiomyoblasts through a mechanism that indirectly involves FBXO32, 60 could support the triggering of an apoptotic process. These observations are in keeping with recently published data showing that the FBXO32 overexpression is not capable to induce apoptosis in the absence of chemotherapeutic drugs, although it is able to enhance the drug-induced pro-apoptotic effect in an 'activated' context. 23 Interestingly, the modulation of JARID2, which can cooperate with components of the PRC2 at muscle-specific promoters in RMS, does not appear to affect H3K27me3 at the FBXO32 promoter suggesting that these two proteins do not cooperate to repress FBXO32 expression in RMS cells, as reported for other target genes. 37, 38 However, an EZH2-dependent regulation of FBXO32 expression in the RMS context is consistent with the observation that FBXO32 transcript levels are inversely correlated with those of EZH2 in patients and significantly reduced as compared with the levels in their normal counterparts. In contrast, EZH2 modulation has different effects in embryonal vs fusionpositive alveolar RMS cells. The embryonal cell subtype, indeed, as observed for myoblasts (refs 11,35,36 and our Supplementary  Figure 2) , undergo myogenic-like differentiation after both EZH2 
(Student's t-test). (b) EZH2
expression levels from analyses of a previously published RMS patient ITCC/CIT data set (Innovative Therapies for Children with Cancer/Carte d'Identité des Tumeurs) within the R2 online platform (R ¼ À 0.5, P ¼ 1.0e À 07) relative to skeletal muscle samples (GSE9103) using the R2 online platform. (c) Negative correlation between EZH2 and FBXO32 expression levels in the RMS patient set using the R2 online platform (R ¼ À 0.5, P ¼ 1.0e À 07).
EZH2 supports PAX3-FOXO1 rhabdomyosarcoma survival R Ciarapica et al genetic silencing 32 and pharmacological inhibition (unpublished observations from our group). Differences in the response to the same treatment of RMS variants are not unusual and are in agreement with both the different cytogenetic and molecular background of fusion-positive alveolar RMS also related to the expression of PAX-FOXO1 chimeric proteins. 1, 2, [61] [62] [63] [64] [65] Collectively, our data suggest that in PAX3-FOXO1 alveolar RMS EZH2 supports tumor cell survival at least in part by repressing FBXO32.
Very recently, some highly specific EZH2 inhibitors have been discovered and published. 26, 27, 29 In the attempt to evaluate the effect of pharmacologic inhibition of EZH2, we have used DZNep, which has been already shown to induce FBXO32 expression in cancer cells 25, 28, 40, 66 in parallel with an EZH2 catalytic inhibitor, MC1945. 33, 34 Both pharmacological treatments phenocopied the effects of genetic inhibition of EZH2 in vitro enhancing the apoptotic rate of fusion-positive alveolar RMS cells, upregulating FBXO32 and downregulating Myogenin. Moreover, even if higher concentrations of DZNep compared with those used in this study can affect histone methyltransferases other than EZH2, 28 the decrease in H3K27me3, but not in H3K9me3 (another repressive transcriptional mark), observed after treatment with the two compounds suggests a selective function anti-EZH2.
Relevant under a translational point of view, in vivo studies showed that tumor growth is clearly impaired in animals in which the EZH2 function was blocked through the use of two different types of inhibitors, both leading to tumor cell apoptosis. These results suggest that EZH2 downregulation and/or inactivation could have an antitumor effect on PAX3-FOXO1-positive alveolar RMS in vivo being helpful in eradicating cancer cells, also in synergy with conventional chemotherapeutic compounds.
Growing evidence supports the use of epigenetic therapies in adult cancer patients. 67 In addition, in pediatric tumors of different origin, histone methyltransferase could become targets for novel EZH2 supports PAX3-FOXO1 rhabdomyosarcoma survival R Ciarapica et al pharmacological therapies. 68 In summary, the data presented here provide evidence that the overexpression of EZH2 has a fundamental role in supporting the malignant potential of PAX3-FOXO1 alveolar RMS cells and that its depletion and/or inactivation could provide a potential effective strategy to treat these pediatric high-risk RMS. 
MATERIALS AND METHODS

Cell lines
Human PAX3-FOXO1 RMS cell lines RH30 and RH41 were described previously, 6 and RH4 was a gift of C Ponzetto. Normal Human Skeletal Muscle cells (myoblasts) were obtained from PromoCell (Heidelberg, Germany). Supplementary methods describe cell lines and culture in detail.
Nuclear fraction enrichment
Cells were lysed and assayed as previously reported. 6 Western blotting
Western blotting was performed on whole-cell lysates as previously described 6 with antibodies described in Supplementary Methods.
Histone extraction
Cells were collected and washed twice with ice-cold phosphate-buffered saline (PBS) 1X supplemented with 5 mM sodium butyrate. After resuspension in triton extraction buffer (PBS, 0.5% triton X 100 (v/v)) containing 2 mM PMSF and 0.02% (w/v) NaN3 at a cell density of 10 7 cells/ml, cells were lysated on ice for 10 min. Lysates were centrifuged at 2000 r.p.m. for 10 min at 4 1C, and the pellets were washed in half volume of triton extraction buffer and centrifuged as before. Pellets were then resuspended in 0.2 N HCl at a cell density of 4 Â 10 7 cells/ml and histones were extracted O/N at 4 1C. Samples were then centrifuged and supernatants were used for western blot analysis.
Transient RNA interference Real-time qRT-PCR Total RNA was extracted using TRizol according to the manufacturer's instructions (Invitrogen), and qRT-PCR was performed as described. 6 Taqman gene assays for GAPDH, EZH2, Myogenin and MCK were from Applied Biosystems (Life Technologies, Carlsbad, CA, USA) (Hs99999905_m1, Hs01072232_m1, Hs00176490_m1). Murine Ezh2, FBXO32, BIM and BAX mRNAs were quantified through the SYBR-green method (Applied Biosystems) with primers previously reported 23 or available on request.
Retroviral infections
The PMN-GFP retroviral vector expressing cMyc-tagged FBXO32 or control PMN-GFP empty vector was previously reported. 23 The pMSCV-GFP retroviral vector (Addgene, Cambridge, MA, USA) expressing flag-tagged murine EZH2 or control pMSCV-GFP empty vector was from G Caretti. Phoenix ampho cells obtained from ATCC were cultured in DMEM supplemented with 10% FBS and transiently transfected using lipofectamine (Invitrogen, Life Technologies). Supernatant containing viral particles collected after 48 h was used to infect RMS cells O/N in the presence of 5 mg/ml of polybrene (two rounds of infection).
Cell proliferation, cell cycle and apoptosis assays For proliferation, cells were collected and counted at the reported time points. For cell cycle analysis, cells were collected 24 h after the second round of silencing and treated as previously reported. 6 For quantification of apoptosis, cells were stained in calcium-binding buffer with APCconjugated Annexin V and 7-Aminoactinomycin D (7-AAD) using the Annexin V apoptosis detection kit (BD Pharmingen, San Diego, CA, USA), according to the manufacturer's recommendations. Cells were analyzed by a fluorescence-activated cell sorting using a FACSCantoII equipped with FACSDiva 6.1 CellQuest software (Becton Dickinson Instrument, San Jose, CA, USA).
Gene expression analysis Affymetrix U133A plus 2.0 profiling data from 101 previously described patient samples 1 were analyzed using the R2 platform (Reference) using the 225328_at probe to detect FBXO32 and the 203358_s_at probe to detect EZH2 mRNA levels. The GSE9103 normal skeletal muscle data set within R2 was used for comparisons of FBXO32 levels between skeletal muscle and RMS patient samples.
Chromatin immunoprecipitation
The chromatin immunoprecipitation assay was performed as previously described. 71 The following antibodies were used: anti-H3K27me3 (EMD Millipore Corporation, Billerica, MA, USA) and anti-EZH2 (Diagenode s.a. Liège, Belgium). Real-time PCR was performed on input samples and equivalent amounts of immunoprecipitated material with the SYBR Green Master Mix (Applied Biosystems) with primers spanning FBXO32 23 and SMAD6 promoter regions as specified in the text (primer sequences available on request).
EZH2 inhibitory assay
The inhibitory assay for MC1945 against EZH2 has been already reported. 34 Xenograft experiments and immunohistochemistry Athymic 6-week-old female BALB/c nude mice (nu þ \nu þ ) were purchased from Charles River Laboratories (Calco (Lecco), Italy). Procedures involving animals were conformed to the institutional guidelines that comply with the national and international laws and policies (EEC Council Directive 86\609, OJ L 358, 12 December 1987). Animals were inoculated subcutaneously into the posterior flanks with RH30 cell suspensions in PBS (5 Â 10 6 cells) and, when the tumors became palpable, intraperitoneally injected (5 mice/group) either with DZNep (2.5 mg/kg) or normal saline (vehicle) or with MC1945 (2.5 mg/kg) or DMSO (vehicle) twice daily, 3 days per week for 3 weeks when mice were killed with no visible signs of toxicity. 34, 72 Tumor volume was measured as reported. 6 Sections from paraffin-embedded excised xenografts were stained with hematoxylin/ eosin or immunohistochemically stained for EZH2 and Ki67 expression with antibodies and detection/acquisition methods reported below.
Immunohistochemistry on RMS primary tissues
Archival, de-identified formalin-fixed, paraffin-embedded PAX3-FOXO1 primary RMS and skeletal muscle control tissues were obtained from the Ospedale Pediatrico Bambino Gesù in Roma, University of Padova and Istituto Tumori di Milano, (Italy) after approval of the respective Institutional Review Boards. Clinicopathological characteristics of the cohort are reported in Supplementary Table 1 . Histopathological features of the tumors were reviewed by a Pathologist of each Institution (RB, RA and PC) blinded to immunohistochemical results. Sections from RMS samples and four muscle tissue specimens were immunostained for EZH2 (Transduction Laboratories, BD, Franklin Lakes, NJ, USA) 73 and Ki67 (Novocastra, Newcastle upon Tyne, UK), and EnVision System-HRP (Power vision Plus method, Zymed, San Francisco, CA, USA) or Biotinilated link (DAKO, Carpintera, CA, USA) secondary antibodies were used followed by staining with 3-amino-9-ethylcarbazolo or 3,3'-diaminobenzidine (chromogen kits, DAKO) and counterstaining with Gill's hematoxylin (Bio-Optica, Milan, Italy). Negative controls were simultaneously stained either with isotype non-specific IgG or omitting the primary antibody. Each section was observed using an Eclipse E600 microscope (Nikon, Sesto Fiorentino, Firenze, Italy) and images were acquired through LUCIA software, version 4.81 (Nikon, Sesto Fiorentino, Firenze, Italy) with a Nikon Digital Camera DXM1200F.
Statistical analysis
The Student's t-test was performed to assess the difference between various treatments. Po0.05 was defined as the statistic significance. Continuous variables were analyzed by the Mann À Whitney U-test or the Kruskal À Wallis test for pairwise or multiple comparisons, respectively. Statistical significance was set at a two-tailed P-value o0.05. All analyses were performed with SPSS 11.5. 
